Skip to main page content
Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

My NCBI Filters
Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1961 2
1962 2
1967 2
1968 1
1969 1
1970 1
1974 1
1977 2
1978 2
1979 3
1980 2
1981 1
1982 2
1983 3
1984 3
1986 8
1987 3
1988 5
1989 6
1990 2
1992 6
1993 2
1994 6
1995 4
1996 8
1997 6
1998 12
1999 5
2000 18
2001 19
2002 14
2003 23
2004 19
2005 26
2006 26
2007 30
2008 32
2009 35
2010 37
2011 43
2012 52
2013 59
2014 63
2015 79
2016 74
2017 80
2018 63
2019 73
2020 100
2021 101
2022 5
Text availability
Article attribute
Article type
Publication date

Search Results

1,039 results
Results by year
Filters applied: . Clear all
Page 1
Avelumab plus Axitinib versus Sunitinib for Advanced Renal-Cell Carcinoma.
Motzer RJ, Penkov K, Haanen J, Rini B, Albiges L, Campbell MT, Venugopal B, Kollmannsberger C, Negrier S, Uemura M, Lee JL, Vasiliev A, Miller WH Jr, Gurney H, Schmidinger M, Larkin J, Atkins MB, Bedke J, Alekseev B, Wang J, Mariani M, Robbins PB, Chudnovsky A, Fowst C, Hariharan S, Huang B, di Pietro A, Choueiri TK. Motzer RJ, et al. Among authors: uemura m. N Engl J Med. 2019 Mar 21;380(12):1103-1115. doi: 10.1056/NEJMoa1816047. Epub 2019 Feb 16. N Engl J Med. 2019. PMID: 30779531 Free PMC article. Clinical Trial.
Updated efficacy results from the JAVELIN Renal 101 trial: first-line avelumab plus axitinib versus sunitinib in patients with advanced renal cell carcinoma.
Choueiri TK, Motzer RJ, Rini BI, Haanen J, Campbell MT, Venugopal B, Kollmannsberger C, Gravis-Mescam G, Uemura M, Lee JL, Grimm MO, Gurney H, Schmidinger M, Larkin J, Atkins MB, Pal SK, Wang J, Mariani M, Krishnaswami S, Cislo P, Chudnovsky A, Fowst C, Huang B, di Pietro A, Albiges L. Choueiri TK, et al. Among authors: uemura m. Ann Oncol. 2020 Aug;31(8):1030-1039. doi: 10.1016/j.annonc.2020.04.010. Epub 2020 Apr 25. Ann Oncol. 2020. PMID: 32339648 Free PMC article. Clinical Trial.
Cell-to-Cell Transmission of Tau and α-Synuclein.
Uemura N, Uemura MT, Luk KC, Lee VM, Trojanowski JQ. Uemura N, et al. Among authors: uemura mt. Trends Mol Med. 2020 Oct;26(10):936-952. doi: 10.1016/j.molmed.2020.03.012. Epub 2020 May 1. Trends Mol Med. 2020. PMID: 32371172 Free PMC article. Review.
HTRA1-Related Cerebral Small Vessel Disease: A Review of the Literature.
Uemura M, Nozaki H, Kato T, Koyama A, Sakai N, Ando S, Kanazawa M, Hishikawa N, Nishimoto Y, Polavarapu K, Nalini A, Hanazono A, Kuzume D, Shindo A, El-Ghanem M, Abe A, Sato A, Yoshida M, Ikeuchi T, Mizuta I, Mizuno T, Onodera O. Uemura M, et al. Front Neurol. 2020 Jul 3;11:545. doi: 10.3389/fneur.2020.00545. eCollection 2020. Front Neurol. 2020. PMID: 32719647 Free PMC article. Review.
Atezolizumab plus bevacizumab versus sunitinib in patients with previously untreated metastatic renal cell carcinoma (IMmotion151): a multicentre, open-label, phase 3, randomised controlled trial.
Rini BI, Powles T, Atkins MB, Escudier B, McDermott DF, Suarez C, Bracarda S, Stadler WM, Donskov F, Lee JL, Hawkins R, Ravaud A, Alekseev B, Staehler M, Uemura M, De Giorgi U, Mellado B, Porta C, Melichar B, Gurney H, Bedke J, Choueiri TK, Parnis F, Khaznadar T, Thobhani A, Li S, Piault-Louis E, Frantz G, Huseni M, Schiff C, Green MC, Motzer RJ; IMmotion151 Study Group. Rini BI, et al. Among authors: uemura m. Lancet. 2019 Jun 15;393(10189):2404-2415. doi: 10.1016/S0140-6736(19)30723-8. Epub 2019 May 9. Lancet. 2019. PMID: 31079938 Clinical Trial.
Recapitulating the human segmentation clock with pluripotent stem cells.
Matsuda M, Yamanaka Y, Uemura M, Osawa M, Saito MK, Nagahashi A, Nishio M, Guo L, Ikegawa S, Sakurai S, Kihara S, Maurissen TL, Nakamura M, Matsumoto T, Yoshitomi H, Ikeya M, Kawakami N, Yamamoto T, Woltjen K, Ebisuya M, Toguchida J, Alev C. Matsuda M, et al. Among authors: uemura m. Nature. 2020 Apr;580(7801):124-129. doi: 10.1038/s41586-020-2144-9. Epub 2020 Apr 1. Nature. 2020. PMID: 32238941
High-Fat Diet-Induced Inflammation Accelerates Prostate Cancer Growth via IL6 Signaling.
Hayashi T, Fujita K, Nojima S, Hayashi Y, Nakano K, Ishizuya Y, Wang C, Yamamoto Y, Kinouchi T, Matsuzaki K, Jingushi K, Kato T, Kawashima A, Nagahara A, Ujike T, Uemura M, Pena MDCR, Gordetsky JB, Morii E, Tsujikawa K, Netto GJ, Nonomura N. Hayashi T, et al. Among authors: uemura m. Clin Cancer Res. 2018 Sep 1;24(17):4309-4318. doi: 10.1158/1078-0432.CCR-18-0106. Epub 2018 May 18. Clin Cancer Res. 2018. PMID: 29776955 Free article.
Tuberous sclerosis complex: Recent advances in manifestations and therapy.
Wataya-Kaneda M, Uemura M, Fujita K, Hirata H, Osuga K, Kagitani-Shimono K, Nonomura N; Tuberous Sclerosis Complex Board of Osaka University Hospital. Wataya-Kaneda M, et al. Among authors: uemura m. Int J Urol. 2017 Sep;24(9):681-691. doi: 10.1111/iju.13390. Epub 2017 Jul 1. Int J Urol. 2017. PMID: 28667702 Review.
Risk stratification for the prognosis of patients with chemoresistant urothelial cancer treated with pembrolizumab.
Kobayashi T, Ito K, Kojima T, Kato M, Kanda S, Hatakeyama S, Matsui Y, Matsushita Y, Naito S, Shiga M, Miyake M, Muro Y, Nakanishi S, Kato Y, Shibuya T, Hayashi T, Yasumoto H, Yoshida T, Uemura M, Taoka R, Kamiyama M, Ogawa O, Kitamura H, Nishiyama H; Japan Urological Oncology Group. Kobayashi T, et al. Among authors: uemura m. Cancer Sci. 2021 Feb;112(2):760-773. doi: 10.1111/cas.14762. Epub 2020 Dec 21. Cancer Sci. 2021. PMID: 33283385 Free PMC article.
1,039 results